J. Garde

698 total citations
54 papers, 339 citations indexed

About

J. Garde is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, J. Garde has authored 54 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 11 papers in Cancer Research. Recurrent topics in J. Garde's work include Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (13 papers) and Lung Cancer Diagnosis and Treatment (11 papers). J. Garde is often cited by papers focused on Lung Cancer Treatments and Mutations (24 papers), Lung Cancer Research Studies (13 papers) and Lung Cancer Diagnosis and Treatment (11 papers). J. Garde collaborates with scholars based in Spain, United States and Austria. J. Garde's co-authors include Carlos Camps, Ana Blasco, José García-Sánchez, Óscar Juan, Francisco Aparisi, Rafael Sirera, María José Safont, Roy M. Bremnes, Xabier Mielgo-Rubio and Pedro Acién and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and Annals of Oncology.

In The Last Decade

J. Garde

51 papers receiving 326 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
J. Garde Spain	11	196	168	84	49	49	54	339
Xia He China	10	173 0.9×	132 0.8×	58 0.7×	37 0.8×	59 1.2×	13	322
Miguel J. Sotelo Spain	11	215 1.1×	98 0.6×	107 1.3×	62 1.3×	29 0.6×	34	330
Hitomi Sumiyoshi Okuma Japan	11	209 1.1×	109 0.6×	67 0.8×	65 1.3×	66 1.3×	53	336
Maria Antista Italy	10	205 1.0×	94 0.6×	46 0.5×	61 1.2×	31 0.6×	26	300
İlhan Hacıbekiroğlu Türkiye	9	148 0.8×	118 0.7×	42 0.5×	60 1.2×	23 0.5×	48	260
Julien Volet France	10	262 1.3×	119 0.7×	95 1.1×	51 1.0×	60 1.2×	23	361
Michèle Natale Germany	8	293 1.5×	256 1.5×	32 0.4×	86 1.8×	50 1.0×	25	415
Alfonso Illiano Italy	7	317 1.6×	299 1.8×	108 1.3×	75 1.5×	21 0.4×	9	469
Naohiro Nose Japan	8	219 1.1×	277 1.6×	47 0.6×	118 2.4×	42 0.9×	23	406
Atsushi Takise Japan	12	232 1.2×	375 2.2×	52 0.6×	92 1.9×	56 1.1×	45	503

Countries citing papers authored by J. Garde

Since Specialization

Citations

This map shows the geographic impact of J. Garde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Garde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Garde more than expected).

Fields of papers citing papers by J. Garde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Garde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Garde. The network helps show where J. Garde may publish in the future.

Co-authorship network of co-authors of J. Garde

This figure shows the co-authorship network connecting the top 25 collaborators of J. Garde. A scholar is included among the top collaborators of J. Garde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Garde. J. Garde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fuereder, Thorsten, J. Garde, Juan Garcia, et al.. (2025). Patritumab deruxtecan (HER3-DXd) in patients with active brain metastases of non-small-cell lung cancer (TUXEDO-3): a multicentre, single-arm, phase 2 trial. The Lancet Oncology. 26(11). 1454–1466.

Martín-Martorell, Paloma, Francisco Aparisi, María José Domper-Arnal, et al.. (2024). A real‑world study of clinical characteristics, treatment sequence and outcomes of patients with non-small cell lung cancer and EGFR exon 20 insertion mutations. Clinical & Translational Oncology. 27(6). 2568–2578. 1 indexed citations

Bartsch, Rupert, Marta Vaz Batista, Anna S. Berghoff, et al.. (2024). Patritumab deruxtecan (HER3-DXd) in active brain metastases from metastatic breast and non-small cell lung cancers, and leptomeningeal disease from advanced solid tumors: The TUXEDO-3 phase II trial.. Journal of Clinical Oncology. 42(16_suppl). TPS2091–TPS2091. 5 indexed citations

Garde, J., et al.. (2021). Soluble Biomarkers with Prognostic and Predictive Value in Advanced Non-Small Cell Lung Cancer Treated with Immunotherapy. Cancers. 13(17). 4280–4280. 15 indexed citations

Majem, Margarita, Santiago Viteri, Guillermo López-Vivanco, et al.. (2021). First-line osimertinib in patients with epidermal growth factor receptor–mutant non–small-cell lung cancer and with a coexisting low allelic fraction of Thr790Met. European Journal of Cancer. 159. 174–181. 4 indexed citations

Carles, Joan, Teresa Alonso, B. Mellado González, et al.. (2020). 639P 223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide. Annals of Oncology. 31. S525–S526. 1 indexed citations

Mielgo-Rubio, Xabier, J. Garde, Óscar Juan, & Felipe Couñago. (2020). Stereotactic body radiation therapy: A good dance partner of oligometastatic non-small cell lung cancer to the sound of SINDAS study. World Journal of Clinical Oncology. 11(12). 983–989. 3 indexed citations

Mielgo-Rubio, Xabier, Federico Rojo, Francesc Casas, et al.. (2020). Deep diving in the PACIFIC: Practical issues in stage III non-small cell lung cancer to avoid shipwreck. World Journal of Clinical Oncology. 11(11). 898–917. 8 indexed citations

Garde, J., Paloma Martín-Martorell, Carmen Salvador Coloma, et al.. (2018). Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients. Clinical & Translational Oncology. 20(8). 1072–1079. 46 indexed citations

10.

Gil-Raga, Mireia, et al.. (2018). Molecular subtypes in early colorectal cancer associated with clinical features and patient prognosis. Clinical & Translational Oncology. 20(11). 1422–1429. 11 indexed citations

11.

Karachaliou, Niki, Martina I. Lefterova, Imane Chaib, et al.. (2018). Homology-directed repair (HDR)-defective lung adenocarcinomas (LUACs) in circulating tumor DNA (ctDNA). Annals of Oncology. 29. viii671–viii671. 1 indexed citations

12.

Martín-Moreno, Paloma Leticia, Carmen Salvador Coloma, Xabier Mielgo-Rubio, et al.. (2017). P3.02c-084 Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Patients. Journal of Thoracic Oncology. 12(1). S1328–S1329. 2 indexed citations

13.

Karachaliou, Niki, Daniela Morales-Espinosa, J. Garde, et al.. (2017). P2.06-010 AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study. Journal of Thoracic Oncology. 12(1). S1074–S1075. 1 indexed citations

14.

Garde, J., et al.. (2017). Role of RAS mutation status as a prognostic factor for patients with advanced colorectal cancer treated with first-line chemotherapy based on fluoropyrimidines and oxaliplatin, with or without bevavizumab: A retrospective analysis. Molecular and Clinical Oncology. 6(3). 403–408. 4 indexed citations

15.

Garde, J., et al.. (2016). 144P: Oligometastatic non-small-cell lung cancer (NSCLC) and unresectable primary tumor: Updated retrospective analysis of safety and efficacy of the radical treatment for the primary tumor and the metastases. Journal of Thoracic Oncology. 11(4). S120–S120. 1 indexed citations

16.

Garde, J., et al.. (2015). High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. Clinical & Translational Oncology. 18(4). 405–412. 1 indexed citations

17.

Garde, J., et al.. (2012). Phase II Trial of Concomitant Neoadjuvant Chemotherapy with Oxaliplatin and Capecitabine and Intensity-Modulated Radiotherapy (IMRT) in Rectal Cancer. Journal of Gastrointestinal Cancer. 43(4). 553–561. 10 indexed citations

18.

Camps, Carlos, et al.. (2007). Venous thromboembolic disease in cancer. Optimisation of the use of antithrombotic agents. Clinical & Translational Oncology. 9(3). 161–171. 5 indexed citations

19.

Camps, Carlos, Rafael Sirera, Roy M. Bremnes, et al.. (2006). Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications. Lung Cancer. 52(3). 343–347. 22 indexed citations

20.

Camps, Carlos, et al.. (2005). La eutanasia en el paciente con cáncer y los cuidados continuos. Clinical & Translational Oncology. 7(7). 278–284. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact